Hysteroscopy surgical facilitation.
Conditions
Interventions
Intervention 1: Intervention group: group A, 1000 mg EPO in soft gel capsule(two in each, 500 mg) will receive posterior vaginal fornix 6 hours before hysteroscopy. Intervention 2: Control group: gro
Sponsors
Rasht University of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Women candidates for hysteroscopy
Exclusion criteria
Exclusion criteria: People who need laparoscopy Pregnant women Existence of systemic diseases infection of cervix Existence of cervical anomalies Existence of Mullerian anomalies Contraindication prostaglandins. patients with bleeding disorders consumers of anticoagulants patients with schizophrenia who use phenothiazine patients With epilepsy patients With blood pressure People who need abdominal hysterectomy infection of vaginal Existence of cervical insufficiency Existence of history of cervical biopsy cesarean delivery History of allergies to evening primros
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| First resistance interval. Timepoint: Interval of first resistance based on duration to size of hegar dilator rejected without cervical resistance. Method of measurement: second.;Duration of dilatation to reach Hegar size 10. Timepoint: Interval from start of hysteroscopy hegar to create dilatation. Method of measurement: second.;Duration of hysteroscopy operation. Timepoint: Interval from the time of importing bogey to finishing importing bogey. Method of measurement: Minute.;First hegar size. Timepoint: During hysteroscopy. Method of measurement: Based on maximum dilator size (hegar),Which can be passed internal os without resistance.;Ease of dilatation. Timepoint: During hysteroscopy. Method of measurement: Base on a 5-point Likert scale (excellent, good, average, poor, very poor).;Requires mechanical dilatation. Timepoint: During hysteroscopy. Method of measurement: Based on clinical examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| Uterine and cervicovaginal complications (bleeding, uterine rupture, cervical rupture,false way ) during surgery. Timepoint: during surgery. Method of measurement: See any of the unusual complications: bleeding , uterine rupture, cervical rupture,false way.;Side effects related to the drug used. Timepoint: ?During operation up to 24 hours after surgery. Method of measurement: Occurrence of any of the following undesirable effects: allergic reactions, abdominal pain, nausea, diarrhea, headache, increased bowel movements.;Preoperative pain from medication. Timepoint: Immediately before surgery. Method of measurement: Scoring for pain by the patient using VSA (Zero = no pain) and (ten = unbearable pain). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Farrokhfar
Rasht University of Medical Sciences
Outcome results
None listed